-
Annual General Meeting
Escare Formulations Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.
-
Balance Sheet
The activity Escare Formulations Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was completed.
-
Charges
A charge with State Bank Of India amounted to Rs. 1.00 M with Charge ID 100295910 was registered on 09 Oct 2019. was recorded as a recent event.
-
Director Appointment
Progress on Babita Garg was appointed as a Director was appointed as a Director on 16 Jun 1997 & has been associated with this company since 28 years 7 months . was documented.
-
Director Appointment
The activity Sanjay Kumar Garg was appointed as a Director was appointed as a Director on 16 Jun 1997 & has been associated with this company since 28 years 7 months . was completed.
-
Company Incorporation
Progress on Escare Formulations Private Limited was registered on 16 Jun 1997 with Roc Mumbai & aged 28 years 7 months as per MCA records. was documented.
Escare Formulations Private Limited, a active private limited company, was established on 16 June 1997 in Kalyan West, Maharashtra, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U51900MH1997PTC108783. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Its leadership includes Babita Garg (Director), Sanjay Kumar Garg (Director). It holds ₹1.00 M open charges and no settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Office No. 2, A Wing, Vastu Sidhi, Yogi Dham, Kalyan West, Maharashtra, 421301.
Company Details
- CIN/LLPIN
U51900MH1997PTC108783
- Registration Number
108783
- Incorporation Date
16 June 1997
- Authorized Capital
₹0.10 M
- Paid-Up Capital
₹0.10 M
- ROC Code
Roc Mumbai
-
Listing Status
Unlisted
- Company Status
Active
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 28 Year, 7 Months
- Last Filing with ROC 31 Mar 2025
- Open Charges ₹ 1.00 M
- Revenue Growth 86.17%
- Profit Growth 542.75%
- Ebitda 29.99%
- Net Worth 9.83%
- Total Assets 68.99%
Escare Formulations Private Limited
Company Report FY 2025-2026Comprehensive Company Insights
Explore comprehensive insights into Escare Formulations Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Babita Garg | Director | 16 Jun 1997 | Current |
| Sanjay Kumar Garg | Director | 16 Jun 1997 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Escare Formulations Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 86.17% increase. The company also saw a substantial improvement in profitability, with a 542.75% increase in profit. The company's net worth moved up by a moderate rise of 9.83%.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
******* |
******* |
******* |
******* |
||
| Revenue from Operations |
|
******* |
******* |
******* |
******* |
||
| Total Assets |
|
******* |
******* |
******* |
******* |
||
| Profit or Loss |
|
*******
|
*******
|
*******
|
*******
|
||
| Net Worth |
|
*******
|
*******
|
*******
|
*******
|
||
| EBITDA |
|
******* |
******* |
******* |
******* |
In 2020, Escare Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
-
Promoters: 92.83%
-
Public: 4.10%
-
Others: 3.07%
| FY (2024) | FY (2023) | FY (2022) | FY (2021) | FY (2020) | |
|---|---|---|---|---|---|
| Promoters | 92.83 | 94.62 | 94.55 | 94.55 | 94.55 |
| Public | 4.10 | 3.89 | 3.95 | 3.96 | 3.98 |
| Others | 3.07 | 1.49 | 1.50 | 1.49 | 1.47 |
Reveal ownership structures and financial performance - Get instant access now!
₹1,000,000.00
₹0
- State Bank Of India : 0.10 Cr
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 2019 | State Bank Of India | ₹1.00 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Escare Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
| Employee Date | Number of Employees |
|---|---|
| 2020 | 78,000 |
| 2021 | 80,500 |
| 2022 | 83,200 |
| 2023 | 86,000 |
| 2024 | 89,500 |
| 2025 | 92,000 |
Gain comprehensive insights into the Deals and Valuation data of Escare Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Escare Formulations's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
What is the CIN of Escare Formulations Private Limited?
The CIN of Escare Formulations Private Limited is U51900MH1997PTC108783.
Where is Escare Formulations Private Limited headquartered?
Escare Formulations Private Limited is headquartered at Office No. 2, A Wing, Vastu Sidhi, Yogi Dham, Kalyan West, Maharashtra, 421301.
When was Escare Formulations Private Limited incorporated?
Escare Formulations Private Limited was incorporated on 16 June 1997.
Who are the current directors of Escare Formulations Private Limited?
The current directors of Escare Formulations Private Limited are
What is the primary industry of Escare Formulations Private Limited?
The primary industry of Escare Formulations Private Limited is Trade.
Is Escare Formulations Private Limited a listed company?
Escare Formulations Private Limited is unlisted.
What is the capital structure of Escare Formulations Private Limited?
The authorized capital of Escare Formulations Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.
What is the compliance status of Escare Formulations Private Limited?
The compliance status of Escare Formulations Private Limited is Compliant.
+91-XXXXXXXXXX